drugset

drugset / Trial / NCT00817414

A Study to Evaluate the Effects of LCI699 on Cortisol in Participants With Hypertension

NCT00817414 ↗

Phase 2 Completed 63 enrolled Novartis Great Lakes Drug Development, Inc. · collab Integrium · collab

RandomizedSequentialDouble-blindTreatment

Summary

This study determined the maximum dose of LCI6999 with respect to effect on the ACTH-stimulated cortisol response in participants with hypertension.

Timeline

Start: 2009-01-14
Primary completion: 2009-08-12
Completion: 2009-08-12

Publications

Schumacher CD, Steele RE, Brunner HR. Aldosterone synthase inhibition for the treatment of hypertension and the derived mechanistic requirements for a new therapeutic strategy. J Hypertens. 2013 Oct;31(10):2085-93. doi: 10.1097/HJH.0b013e328363570c.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	osilodrostat	Small molecule	0.5 mg	Oral
Subject	osilodrostat	Small molecule	1 mg	Oral
Subject	osilodrostat	Small molecule	2 mg	Oral

Indications